Results 71 to 80 of about 1,428 (167)

SGLT2 gene expression in thirst‐promoting NOS1 neurons and vasopressin‐synthesizing neurons in male rats

Physiological Reports, Volume 14, Issue 17, September 2026.
Abstract While sodium–glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects, they cause only mild changes in body fluid balance, partly through compensatory increases in water intake and vasopressin (AVP) secretion. However, whether SGLT2 inhibitors directly influence central pathways governing these fluid‐regulatory responses remains ...
Takahiro Masuda, Masahide Yoshida, Young Chul Kim, Volker Vallon, Yoshiyuki Morishita, Daisuke Nagata, Tatsushi Onaka   +6 more
wiley   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1310-1321, August 2026.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

Issue Information

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1453-1456, September 2026.
wiley   +3 more sources

Reductions in liver enzymes are associated with anti‐hyperglycaemic and anti‐obesity effects of tofogliflozin in people with type 2 diabetes: Post‐hoc analyses

Endocrinology, Diabetes & Metabolism
Aims How the pathology of type 2 diabetes (T2D), including hyperglycaemia and obesity, affects liver enzymes has not been clinically demonstrated. Thus, we compared time courses of gamma‐glutamyltransferase (GGT) and alanine aminotransferase (ALT) with ...
Toshinari Takamura, Kohei Kaku, Akihiro Yoshida, Hiromi Kusakabe, Hiroyuki Nakamura, Hideki Suganami   +5 more
doaj   +1 more source

Effect of tofogliflozin on adipose immune cells of obese mice.

, 2019
Mice were fed either HFD or NC with/without tofogliflozin. (A) Body weight, epididymal VAT (eVAT) weight, liver weight, and kidney weight (n = 6 per group). (B) Fasting blood glucose and insulin level.
Kohsuke Shirakawa (4233655), Keisuke Inoue (764054), Jin Endo (4233664), Wataru Yano (764051), Yoshinori Katsumata (630787), Motoaki Sano (276939)   +5 more
core   +1 more source

Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH)

FEBS Open Bio, 2019
The rise in the incidence of nonalcoholic steatohepatitis (NASH) has necessitated the development of an effective prevention methodology. An antidiabetic drug, belonging to the group of sodium glucose cotransporter 2 (SGLT2) inhibitors, has been tested ...
Ryo Goto, Kenya Kamimura, Yoko Shinagawa‐Kobayashi, Norihiro Sakai, Takuro Nagoya, Yusuke Niwa, Masayoshi Ko, Kohei Ogawa, Ryosuke Inoue, Takeshi Yokoo, Akira Sakamaki, Hiroteru Kamimura, Satoshi Abe, Hiroshi Nishina, Shuji Terai   +14 more
doaj   +1 more source

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates   +7 more
wiley   +1 more source

Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study

Journal of Diabetes Investigation, 2020
Recent studies have shown that sodium–glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood.
Mayu Tochiya, Hisashi Makino, Tamiko Tamanaha, Miki Matsuo, Ai Hishida, Ryo Koezuka, Yoko Ohata, Tsutomu Tomita, Choel Son, Yoshihiro Miyamoto, Satoshi Yasuda, Kiminori Hosoda   +11 more
doaj   +1 more source

Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study

, 2019
Background: We have found that anagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4) significantly ameliorates arterial stiffness in Type 2 Diabetes Mellitus (T2DM) patients compared with an equivalent hypoglycaemic agent, glimepiride.
Yoshihiro Fukumoto, Jiahui Sun, Nobuhiro Tahara, Sho-ichi Yamagishi, Tomohisa Nakamura, Akihiro Honda, Sachiyo Igata, Yoichi Sugiyama, Munehisa Bekki, Takanori Matsui, Yuki Kumashiro, Atsuko Tahara   +11 more
core   +1 more source

From HBV to MASLD Cirrhosis: Mechanistic Insights and Therapeutic Strategies

Portal Hypertension &Cirrhosis, Volume 5, Issue 2, Page 170-188, June 2026.
This review examines the epidemiological shift from hepatitis B virus (HBV) to metabolic dysfunction‐associated steatotic liver disease (MASLD) as the leading cause of cirrhosis globally. It highlights the distinct pathogenic mechanisms between HBV and MASLD cirrhosis and discusses evolving diagnostic tools and therapeutic strategies tailored to the ...
Hanqi Yu, Hongfan Ding, Yang Huang, Haoze Cao, Yuan Ding, Weilin Wang   +5 more
wiley   +1 more source